Status:
COMPLETED
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Lead Sponsor:
Eli Lilly and Company
Conditions:
Hepatic Insufficiency
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared t...
Eligibility Criteria
Inclusion
- Participants have given written informed consent approved by the ethical review board (ERB) governing the site
- Female participants should be of non-childbearing potential
- Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m\^2)
- Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
- Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)
Exclusion
- Has had esophagus variceal bleeding within 3 months of check-in
- Have the need to take medications that may interfere with how the liver removes the drug
- Have evidence of cancer in the liver
- Consumes excessively large amounts of drinks with caffeine or alcohol
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01836185
Start Date
April 1 2013
End Date
October 1 2013
Last Update
October 12 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Miami, Florida, United States, 33169
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States, 32806